Loading clinical trials...
Loading clinical trials...
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Eli Lilly and Company
NCT06735833 · Migraine
NCT06810505 · Chronic Migraine
NCT06241313 · Migraine
NCT07071506 · Migraine, Migraine With or Without Aura, and more
NCT06641466 · Menstrual Migraine
21st Century Neurology
Phoenix, Arizona
Medical Center for Clinical Research
San Diego, California
Sensible Healthcare
Ocoee, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions